Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04248543
Other study ID # Pro00103960
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 22, 2020
Est. completion date December 2024

Study information

Verified date January 2024
Source Duke University
Contact Taylor Fryman, BS
Phone (919) 668-3726
Email taylor.fryman@duke.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if quantitative magnetic resonance imaging (qMRI) can objectively measure changes in the tumor/vertebral body and adjacent spinal cord following stereotactic body radiation therapy (SBRT) for painful metastatic spine disease.


Description:

Metastatic spine disease (MSD) can result in considerable morbidity from pain, spinal cord compromise and neurologic disability. Recent developments in image-guidance and immobilization have enabled more accurate target localization, which allows methods of precise high-dose radiation delivery such as stereotactic body radiation therapy (SBRT). SBRT carries potential risks of radiation induced myelopathy (RIM) and vertebral compression fracture (VCF). Magnetic resonance imaging (MRI) is a sensitive imaging modality that may be able to detect radiation-induced damage in the vertebral body or spinal cord following SBRT. Quantitative MR-based imaging methods may also help to quantify treatment response and help predict subsequent outcomes such as tumor control and VCF risk.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - A diagnosis of metastatic cancer with a vertebral body metastasis or contiguous vertebral body metastases for which SBRT is appropriate - Age = 18 years of age - KPS = 70 - Life expectancy of at least 3 months - No contraindication to undergoing MR imaging - Women of childbearing age must have a negative urine or serum pregnancy test to meet eligibility per Duke Policy - Pre-treatment pain score of at least 1/10 based on the numeric pain rating scale (NPRS) - Disease located from C1 to S5 - Subjects with prior radiation to the involved vertebral body are allowed. Exclusion Criteria: - Subjects unable to undergo MRI (includes non-MRI compatible material or devices and severe claustrophobia) - Subjects with prior procedural intervention to the involved vertebral body that would result in artifact (kyphoplasty, screw and/or rod placement); minimally invasive surgery without instrumentation of the involved vertebral body and instrumentation immediately above or below the index lesion is allowed. - Subjects with spinal cord compression; minimally invasive "separation" surgery to first resect the epidural component is allowed - Pregnant or breast-feeding women - Allergy to standard IV contrast agents used in MRI - Subjects with eGFR <30 30 mL/min2 or on dialysis

Study Design


Related Conditions & MeSH terms


Intervention

Device:
qMRI with Gadoteridol contrast agent
quantitative MR: MRI uses a magnet and radio waves to make medical images of the body. Gadoteridol is used as a contrast agent. Quantitative MRI involves the use of software to analyze the acquired images.

Locations

Country Name City State
United States Duke Cancer Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Relative Change in Sequence specific parameters for Diffusion tensor imaging (DTI) baseline, 4 wks
Primary Relative Change in Sequence specific parameters for Diffusion weighted imaging (DWI) baseline, 4 wks
Primary Relative Change in Sequence specific parameters for Dynamic contrast enhanced (DCE) MRI baseline, 4 wks
Secondary Change in numeric pain score as measured by the Numeric Pain Rating Scale Measured from 0-10 with 0 being no pain and 10 being severe pain baseline, 4 wks
Secondary Change in numeric pain score as measured by the Brief Pain Inventory Measured from 0-10 with 0 being no pain and 10 being worst imaginable pain baseline, 4 wks
Secondary Change in numeric pain score as measured by the EQ5D Pain Questionnaire Measured from 0-10 with 0 being no pain and 10 being worst imaginable pain baseline, 4 wks
Secondary Change in opioid use baseline, 4 wks
Secondary Change in quality of life as measured by the Pat Sf36 V2 assessment Pat SF36 V2 is a quality of life survey about physical activity, general health and daily functions measured from excellent/much better/yes, limited a lot/all of the time/not at all, through poor/much worse/no,not limited at all/none of the time/extremely with additional not answered option baseline, 4 wks
Secondary Change in quality of life as measured by the PROMIS assessment PROMIS categories include physical function, anxiety, depression, fatigue, sleep and pain ranging from never/not at all through always/very much. baseline, 4 wks
Secondary Change in quality of life as measured by the SOSG+ assessment Questionnaire about physical function, neurological function and pain ranging from never/not at all through always/very much baseline, 4 wks
See also
  Status Clinical Trial Phase
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Terminated NCT00593320 - Stereotactic Radiosurgery (SRS) for Spine Metastases N/A
Recruiting NCT05575323 - Randomized Trial on Same-day SBRT and Surgical Stabilization for Symptomatic Spinal Metastases N/A
Completed NCT02987153 - Kypho-Intra Operative Radiation Therapy (IORT) for Localized Spine Metastasis, Phase I/II Study N/A
Recruiting NCT03363685 - Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis
Terminated NCT02407795 - Conventional With Stereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases N/A
Completed NCT01365715 - Preoperative Embolization in Surgical Treatment of Spinal Metastases. N/A
Recruiting NCT04863612 - SBRT in the Management of Solid Spinal Metastases
Recruiting NCT04242589 - Trial of Combined Radiotherapy and Vertebroplasty for Patients With Painful Metastatic Spinal Lesions Phase 2
Recruiting NCT01849510 - Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost Phase 2
Not yet recruiting NCT06244264 - The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis N/A
Not yet recruiting NCT06220071 - Multicentric European Study In Patients With Vertebral Metastases
Completed NCT01290562 - Stereotactic Body Radiotherapy (SBRT) for Spinal/Para-Spinal Metastases (Spine SBRT) Phase 2
Recruiting NCT06120426 - En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.
Completed NCT03224650 - Validation of Novel Predictive Score for Patients With Spinal Metastases
Completed NCT02512965 - Study Comparing Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy (CRT) for Spinal Metastases N/A
Not yet recruiting NCT06093854 - Intraoperative Radiotherapy in Treating Spinal Metastases N/A
Completed NCT02364115 - Randomized Trial Comparing Conventional Radiotherapy With Stereotactic Radiotherapy in Patients With Bone Metastases - VERTICAL Study N/A
Recruiting NCT03398915 - The European Robotic Spinal Instrumentation (EUROSPIN) Study
Not yet recruiting NCT05173467 - Robot-assisted Invasion-controlled Surgery Versus Traditional-open Surgery Against Metastatic Spinal Tumor N/A